Leann Tilley Selected Research

Malaria

1/2022	Dimeric Artesunate Glycerophosphocholine Conjugate Nano-Assemblies as Slow-Release Antimalarials to Overcome Kelch 13 Mutant Artemisinin Resistance.
1/2022	Reaction hijacking of tyrosine tRNA synthetase as a new whole-of-life-cycle antimalarial strategy.
1/2022	Cell biological analysis reveals an essential role for Pfcerli2 in erythrocyte invasion by malaria parasites.
1/2021	Violacein-Induced Chaperone System Collapse Underlies Multistage Antiplasmodial Activity.
1/2021	Non-canonical metabolic pathways in the malaria parasite detected by isotope-tracing metabolomics.
1/2021	Biochemical and cellular characterisation of the Plasmodium falciparum M1 alanyl aminopeptidase (PfM1AAP) and M17 leucyl aminopeptidase (PfM17LAP).
1/2020	Role of Plasmodium falciparum Protein GEXP07 in Maurer's Cleft Morphology, Knob Architecture, and P. falciparum EMP1 Trafficking.
1/2020	K13, the Cytostome, and Artemisinin Resistance.
12/2019	The Metabolite Repair Enzyme Phosphoglycolate Phosphatase Regulates Central Carbon Metabolism and Fosmidomycin Sensitivity in Plasmodium falciparum.
11/2019	The structure of the PA28-20S proteasome complex from Plasmodium falciparum and implications for proteostasis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Leann Tilley Research Topics

Disease

59	Malaria 01/2022 - 03/2002
8	Infections 01/2020 - 10/2005
5	Parasitemia 11/2021 - 12/2007
3	Falciparum Malaria (Plasmodium falciparum Malaria) 01/2016 - 12/2007
2	Neoplasms (Cancer) 01/2021 - 01/2021
2	Hypersensitivity (Allergy) 12/2017 - 03/2013
2	Rupture 02/2012 - 03/2010
1	Hematologic Diseases (Blood Diseases) 12/2014
1	Inflammation (Inflammations) 08/2010
1	Blister (Bulla) 02/2003

Drug/Important Bio-Agent (IBA)

24	Proteins (Proteins, Gene)FDA Link 01/2020 - 08/2002
11	Antimalarials (Antimalarial Agents)IBA 01/2021 - 11/2007
11	Pharmaceutical PreparationsIBA 12/2019 - 02/2004
9	artemisinin (artemisinine)IBA 01/2022 - 07/2011
7	Heme (Haem)IBA 01/2020 - 03/2002
7	Hemoglobins (Hemoglobin)IBA 01/2020 - 07/2003
4	Hemin (Panhematin)FDA Link 10/2017 - 03/2002
4	Chloroquine (Aralen)FDA LinkGeneric 02/2010 - 04/2004
3	artenimol (dihydroartemisinin)IBA 11/2019 - 01/2017
3	hemozoinIBA 10/2017 - 08/2010
3	LipidsIBA 10/2014 - 02/2003
2	Biological ProductsIBA 01/2022 - 01/2021
2	CarbonIBA 01/2021 - 12/2019
2	SpectrinIBA 01/2018 - 12/2017
2	4-aminoquinolineIBA 08/2013 - 10/2005
1	Liposomes (Liposome)IBA 01/2022
1	Adenosine (Adenocard)FDA LinkGeneric 01/2022
1	Tyrosine (L-Tyrosine)FDA Link 01/2022
1	Indicators and Reagents (Reagents)IBA 01/2022
1	1,2- diarachidonoyl- glycero- 3- phosphocholineIBA 01/2022
1	ArtemisininsIBA 01/2022
1	Lumefantrine Drug Combination Artemether (Coartem)FDA Link 11/2021
1	violaceinIBA 01/2021
1	Bortezomib (Velcade)FDA Link 01/2021
1	AminopeptidasesIBA 01/2021
1	IsotopesIBA 01/2021
1	AntigensIBA 01/2020
1	Glucose (Dextrose)FDA LinkGeneric 12/2019
1	Terpenes (Terpenoids)IBA 01/2019
1	1,2,4-trioxaneIBA 01/2018
1	Proteasome Endopeptidase Complex (Proteasome)IBA 01/2018
1	Ethylnitrosourea (N-Ethyl-N-nitrosourea)IBA 12/2017
1	piperaquineIBA 04/2017
1	Proteasome InhibitorsIBA 02/2016
1	SuspensionsIBA 05/2014
1	PlasticsIBA 10/2012
1	quinolineIBA 08/2010
1	E 64IBA 03/2010
1	Virulence Factors (Pathogenicity Factors)IBA 08/2008
1	AntibodiesIBA 12/2007
1	Lipoproteins (Lipoprotein)IBA 09/2007
1	CholesterolIBA 05/2006
1	Primaquine FDA Link 10/2005
1	EnzymesIBA 09/2005
1	Phospholipids (Phosphatides)FDA LinkGeneric 10/2004
1	Surface Antigens (Surface Antigen)IBA 10/2004
1	Reactive Oxygen Species (Oxygen Radicals)IBA 02/2004
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 02/2004
1	Plasmodium falciparum erythrocyte membrane protein 1IBA 11/2003
1	Protein Sorting Signals (Signal Peptide)IBA 02/2003
1	4,4- difluoro- 4- bora- 3a,4a- diaza- s- indacene (BODIPY)IBA 02/2003
1	Green Fluorescent ProteinsIBA 02/2003
1	CeramidesIBA 02/2003
1	Coatomer Protein (Archain)IBA 08/2002

Therapy/Procedure

3	Therapeutics 01/2018 - 04/2015
1	Synchrotrons 04/2009